CN1286632A - 嘌呤核苷用于调节中枢神经系统神经元的轴突突出生长 - Google Patents

嘌呤核苷用于调节中枢神经系统神经元的轴突突出生长 Download PDF

Info

Publication number
CN1286632A
CN1286632A CN98810807A CN98810807A CN1286632A CN 1286632 A CN1286632 A CN 1286632A CN 98810807 A CN98810807 A CN 98810807A CN 98810807 A CN98810807 A CN 98810807A CN 1286632 A CN1286632 A CN 1286632A
Authority
CN
China
Prior art keywords
purine nucleosides
analog
nervous system
central nervous
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98810807A
Other languages
English (en)
Chinese (zh)
Inventor
L·I·贝诺维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CN1286632A publication Critical patent/CN1286632A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CN98810807A 1997-09-02 1998-02-20 嘌呤核苷用于调节中枢神经系统神经元的轴突突出生长 Pending CN1286632A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/921,902 1997-09-02
US08/921,902 US6440455B1 (en) 1997-09-02 1997-09-02 Methods for modulating the axonal outgrowth of central nervous system neurons

Publications (1)

Publication Number Publication Date
CN1286632A true CN1286632A (zh) 2001-03-07

Family

ID=25446158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98810807A Pending CN1286632A (zh) 1997-09-02 1998-02-20 嘌呤核苷用于调节中枢神经系统神经元的轴突突出生长

Country Status (12)

Country Link
US (8) US6440455B1 (enExample)
EP (2) EP1009412B1 (enExample)
JP (1) JP4601816B2 (enExample)
KR (1) KR100564789B1 (enExample)
CN (1) CN1286632A (enExample)
AT (1) ATE271874T1 (enExample)
AU (1) AU748961B2 (enExample)
CA (1) CA2302156C (enExample)
DE (1) DE69825292T2 (enExample)
NZ (1) NZ503073A (enExample)
RU (1) RU2212241C2 (enExample)
WO (1) WO1999011274A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020140730A1 (zh) * 2018-12-30 2020-07-09 广州君赫生物科技有限公司 硫鸟嘌呤在制备治疗adsl缺陷症药物中应用

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
KR20070051953A (ko) * 1998-11-02 2007-05-18 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US7582680B1 (en) 1998-11-12 2009-09-01 Purdue Research Foundation Methods and compositions for treating mammalian spinal cord injuries
US7172871B1 (en) * 2000-09-07 2007-02-06 Children's Medical Center Corporation Methods and compositions for modulating axonal outgrowth of central nervous system neurons
FR2814077A1 (fr) * 2000-09-20 2002-03-22 Inst Nat Sante Rech Med Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
NZ543953A (en) 2001-04-24 2007-04-27 Univ Chicago Method and compositions for treating mammalian nerve tissue injuries
US7147647B2 (en) * 2002-04-26 2006-12-12 Medtronic, Inc. Sintered titanium tube for the management of spinal cord injury
US20040106896A1 (en) * 2002-11-29 2004-06-03 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US7813473B2 (en) * 2002-07-23 2010-10-12 General Electric Company Method and apparatus for generating temporally interpolated projections
US6904118B2 (en) * 2002-07-23 2005-06-07 General Electric Company Method and apparatus for generating a density map using dual-energy CT
WO2004022039A2 (en) * 2002-09-03 2004-03-18 Neurological Technologies Inc. Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
JP2006501936A (ja) * 2002-10-04 2006-01-19 エラン ファーマ インターナショナル，リミティド 固体ナノ粒子活性薬剤のガンマ線照射
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US7199110B2 (en) * 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
CA2523035C (en) * 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
GB0312844D0 (en) * 2003-06-04 2003-07-09 Paradigm Therapeutics Ltd Use of compounds in medicine
WO2005016359A1 (en) * 2003-08-19 2005-02-24 Neurological Technologies Inc. Method of promoting remyelination
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
WO2006020365A2 (en) * 2004-07-26 2006-02-23 The Regents Of The University Of California Method for prevention or treatment of inflamatory disease
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
WO2006111348A1 (de) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Verwendung von heparin und heparinderivaten zur modulation des neuritenwachstum-kontrollierenden nogo-rezeptors
WO2007039256A2 (de) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
AU2007234006A1 (en) * 2006-03-31 2007-10-11 Adenobio N.V. Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment
US20080317843A1 (en) * 2006-07-12 2008-12-25 Elan Corporation Plc Nanoparticulate formulations of modafinil
US8419710B2 (en) * 2006-12-06 2013-04-16 Medtronic, Inc. Methods for infusing fluids via an implantable infusion system
US20080270686A1 (en) * 2007-04-26 2008-10-30 Grannan Michael F Methods and system to cache content on a vehicle
US8133861B2 (en) * 2008-02-29 2012-03-13 Alseres Pharmaceuticals, Inc. Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
DK2502623T3 (en) 2008-06-06 2016-07-04 Children's Medical Center Corp Promoting axonregeneration the adult cns by management of protein translation
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
MX391536B (es) 2012-01-27 2025-03-21 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
US20140179741A1 (en) * 2012-10-10 2014-06-26 Massachusetts Institute Of Technology Use of chelators of divalent cations to promote nerve regeneration
WO2014096958A1 (en) * 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
RU2517117C2 (ru) * 2012-11-26 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций
JP6153281B1 (ja) * 2015-08-26 2017-06-28 株式会社スタージェン 細胞内ａｔｐ増強剤
EP3797764A1 (en) 2019-09-27 2021-03-31 Janusz Chupty Contissi Pharmacological composition for treatment of nervous tissue dysfunction, in particular viral latency, and the use of j05 atc group substances in treatment of nervous tissue dysfunction, in particular viral latency
WO2021260740A1 (en) * 2020-06-25 2021-12-30 Celagenex Research (India) Pvt. Ltd. Novel synergistic nutritional compositions for promoting axonal regeneration
WO2023055531A1 (en) * 2021-09-28 2023-04-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating peripheral neuropathy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808027A (en) 1972-03-29 1974-04-30 Du Pont Silica surfaced films
US4341868A (en) * 1978-08-18 1982-07-27 Kyowa Hakko Kogyo Co., Ltd. Method and test composition for the determination of the substrate for xanthine oxidase
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
WO1988009335A1 (en) 1987-05-26 1988-12-01 Paul Gordon Polymorphs of inosine and methods of making and using them
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
WO1991004032A1 (en) * 1989-09-15 1991-04-04 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US5187162A (en) 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
RU1755583C (ru) * 1990-10-31 1994-08-30 ВНИИ генетики и селекции промышленных микроорганизмов Способ получения инозина
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
US5483130A (en) * 1992-09-09 1996-01-09 Axelerator, Inc. Structure for accelerating heavy ions with uniformly spaced quadrupole focusing (USQF)
US5422343A (en) * 1992-12-21 1995-06-06 Otsuka Pharmaceutical Factory, Inc. Prophylactic and therapeutic composition for MRSA infection
US5438130A (en) * 1993-01-15 1995-08-01 Cambridge Neuroscience, Inc. Fucosylated guanosine disulfates as excitatory amino acid antagonists
RU2063753C1 (ru) 1993-04-22 1996-07-20 Василий Владимирович Афанасьев Способ лечения экстрапирамидного синдрома при остром отравлении галоперидолом
ATE197672T1 (de) * 1993-08-13 2000-12-15 Seikagaku Kogyo Co Ltd Arzneimittel gegen nervöse erkrankungen
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
RU2098085C1 (ru) * 1994-04-07 1997-12-10 Николай Васильевич Карсанов Антигипоксическое средство
US5447939A (en) * 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
AU4808997A (en) * 1996-09-30 1998-04-24 Brigham And Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
US6440455B1 (en) * 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US6855690B2 (en) * 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
GB2379797A (en) * 2001-09-15 2003-03-19 Zarlink Semiconductor Ab Surface Emitting Laser

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020140730A1 (zh) * 2018-12-30 2020-07-09 广州君赫生物科技有限公司 硫鸟嘌呤在制备治疗adsl缺陷症药物中应用

Also Published As

Publication number Publication date
US7338666B2 (en) 2008-03-04
US20070213294A1 (en) 2007-09-13
RU2000108443A (ru) 2002-02-10
US20040014710A1 (en) 2004-01-22
EP1009412A1 (en) 2000-06-21
JP4601816B2 (ja) 2010-12-22
US20020137721A1 (en) 2002-09-26
US20020055484A1 (en) 2002-05-09
US7935680B2 (en) 2011-05-03
AU6656898A (en) 1999-03-22
KR100564789B1 (ko) 2006-03-28
RU2212241C2 (ru) 2003-09-20
EP1466606A2 (en) 2004-10-13
US20050277614A1 (en) 2005-12-15
AU748961B2 (en) 2002-06-13
US6440455B1 (en) 2002-08-27
ATE271874T1 (de) 2004-08-15
JP2001516695A (ja) 2001-10-02
WO1999011274A1 (en) 1999-03-11
US20020128223A1 (en) 2002-09-12
DE69825292D1 (de) 2004-09-02
EP1466606A3 (en) 2004-11-24
EP1009412B1 (en) 2004-07-28
US6551612B2 (en) 2003-04-22
US20020042390A1 (en) 2002-04-11
CA2302156A1 (en) 1999-03-11
CA2302156C (en) 2006-11-21
DE69825292T2 (de) 2005-05-25
NZ503073A (en) 2002-11-26
HK1029916A1 (en) 2001-04-20
KR20010023578A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
CN1286632A (zh) 嘌呤核苷用于调节中枢神经系统神经元的轴突突出生长
US20160279161A1 (en) Senescence and senescence associated secretory phenotype
Boison et al. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer
López–Cortés et al. Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits
US20180256502A1 (en) Compositions Comprising NAv1.7 Selective Inhibitors For Treating Acute, Post-Operative, Or Chronic Pain And Methods Of Using The Same
EP1631294B1 (en) A method of treating an anxiety disorder
US20050256059A1 (en) Methods and compositions for treatment of neurological disorder
US20120058099A1 (en) Use of hypoxanthine for promotion of neuronal outgrowth
Raboni et al. Conjugation to gold nanoparticles of methionine gamma-lyase, a cancer-starving enzyme. Physicochemical characterization of the nanocomplex for prospective nanomedicine applications
KR20010043803A (ko) 핵산 함유 복합체 제제의 제조 방법
Asin et al. Differential effects of CCK-JMV-180 on food intake in rats and mice
EP4662319A2 (en) Personalized crispr profiling for cancer
HK1029916B (en) Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons
Bennett et al. Activation of cholinergic and adrenergic receptors increases the concentration of extracellular adenosine in the cerebral cortex of unanesthetized rat
WO2009111264A2 (en) Systemic purine administration:modulating axonal outgrowth of central nervous system neurons
HUP0000124A2 (hu) Uridint tartalmazó gyógyszerkészítmények neurodegeneratív rendellenességek kezelésére
Zhalalova et al. NEUROPROTECTIVE APPROACH TO TREATMENT OPTICORETINAL PATHOLOGY
Al Safarjalani et al. Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio) acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy
Volchkov et al. Effect of epidural injection of prosidol with clonidine on the state of spinal cord and spinal ganglion

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned